The focus is on the active substance SNV4818, a so-called PI3Kα inhibitor, which is designed to specifically attack mutated tumour cells without affecting healthy cells. Around 40 per cent of patients with a certain form of breast cancer have corresponding genetic changes that are associated with poorer disease progression. This is precisely where the new approach comes in, promising better tolerability and more stable therapy results.
The strategic value lies in the combination. SNV4818 could be used in the future with established hormone therapies and other agents, thus enabling new treatment regimes. For Novartis, the programme thus fits seamlessly into its focus on personalised medicine and differentiated therapies for clearly defined patient groups. The deal has a clear dimension. Two billion dollars will flow immediately, with further payments linked to milestones. Novartis is thus securing early access to a technology that has the potential to shift existing therapeutic boundaries. The message for the life sciences market is clear. Competition is no longer based solely on new active ingredients, but also on their precision, tolerability and combinability. It is precisely in this area of tension that Novartis is positioning itself with its next step.
News of "Novartis AG" from 20.03.2026